CLINICAL_TRIALS
trial_result
· 2018-01-30
Clinical Trial Update: Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 1, Phase 2]
Summary
A dose-escalation study of ALXN1210 IV in people with paroxysmal nocturnal hemoglobinuria (PNH) has completed Phase 1/2 with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: PNH | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-01-30